Advertisement
| car t therapy lung cancer: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t therapy lung cancer: Lung Cancer and Personalized Medicine Aamir Ahmad, Shirish Gadgeel, 2015-12-14 This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies. |
| car t therapy lung cancer: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t therapy lung cancer: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t therapy lung cancer: Successes and Limitations of Targeted Cancer Therapy S. Peters, R.A. Stahel, 2014-02-19 The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies. |
| car t therapy lung cancer: Lung Cancer Karen L. Reckamp, 2016-08-17 This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer. |
| car t therapy lung cancer: HIV-1 Latency Guido Silvestri, Mathias Lichterfeld, 2018-10-11 This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public. |
| car t therapy lung cancer: Encountering Pain Deborah Padfield, Joanna M. Zakrzewska, 2021-02-15 What is persistent pain? How do we communicate pain, not only in words but in visual images and gesture? How do we respond to the pain of another, and can we do it better? Can explaining how pain works help us handle it? This unique compilation of voices addresses these and bigger questions. Defined as having lasted over three months, persistent pain changes the brain and nervous system so pain no longer warns of danger: it seems to be a fault in the system. It is a major cause of disability globally, but it remains difficult to communicate, a problem both to those with pain and those who try to help. Language struggles to bridge the gap, and it raises ethical challenges in its management unlike those of other common conditions. Encountering Pain shares leading research into the potential value of visual images and non-verbal forms of communication as means of improving clinician–patient interaction. It is divided into four sections: hearing, seeing, speaking, and a final series of contributions on the future for persistent pain. The chapters are accompanied by vivid photographs co-created with those who live with pain. The volume integrates the voices of leading scientists, academics and contemporary artists with poetry and poignant personal testimonies to provide a manual for understanding the meanings of pain, for healthcare professionals, pain patients, students, academics and artists. The voices and experiences of those living with pain are central, providing tools for discussion and future research, shifting register between creative, academic and personal contributions from diverse cultures and weaving them together to offer new understanding, knowledge and hope. |
| car t therapy lung cancer: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| car t therapy lung cancer: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car t therapy lung cancer: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t therapy lung cancer: Respiratory Endoscopy Takehiro Izumo, Shinji Sasada, Tomohiko Aso, Kazuko Nasu, Yasuaki Arai, 2016-11-08 This book provides a detailed overview of the latest innovations in respiratory endoscopy, from both diagnostic and therapeutic perspectives; each chapter focuses on one disease and the techniques for early diagnosis as well as treatment. It comprehensively covers treatment and procedures, including simultaneous X-ray fluoroscopy and its use during bronchoscopic procedures. This fast-developing technology is essential for the medical management of non-malignant and malignant diseases of the chest, especially lung cancer. Respiratory Endoscopy describes the cooperation between all the members of the healthcare team, and as such is a valuable resource not only for medical staff, but also for radiological technicians and nursing staff who contribute significantly in the care of the patients undergoing these invasive procedures. By promoting teamwork and providing practical know-how, it will improve the success and safety of respiratory endoscopy procedures. |
| car t therapy lung cancer: The First Cell Azra Raza, 2019-10-15 With the fascinating scholarship of The Emperor of All Maladies and the deeply personal experience of When Breath Becomes Air, a world-class oncologist examines the current state of cancer and its devastating impact on the individuals it affects -- including herself. In The First Cell, Azra Raza offers a searing account of how both medicine and our society (mis)treats cancer, how we can do better, and why we must. A lyrical journey from hope to despair and back again, The First Cell explores cancer from every angle: medical, scientific, cultural, and personal. Indeed, Raza describes how she bore the terrible burden of being her own husband's oncologist as he succumbed to leukemia. Like When Breath Becomes Air, The First Cell is no ordinary book of medicine, but a book of wisdom and grace by an author who has devoted her life to making the unbearable easier to bear. |
| car t therapy lung cancer: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| car t therapy lung cancer: How Tobacco Smoke Causes Disease United States. Public Health Service. Office of the Surgeon General, 2010 This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products. |
| car t therapy lung cancer: Stereotactic Body Radiation Therapy Simon S. Lo, Bin S. Teh, Jiade J. Lu, Tracey E. Schefter, 2012-08-28 Stereotactic body radiation therapy (SBRT) has emerged as an important innovative treatment for various primary and metastatic cancers. This book provides a comprehensive and up-to-date account of the physical/technological, biological, and clinical aspects of SBRT. It will serve as a detailed resource for this rapidly developing treatment modality. The organ sites covered include lung, liver, spine, pancreas, prostate, adrenal, head and neck, and female reproductive tract. Retrospective studies and prospective clinical trials on SBRT for various organ sites from around the world are examined, and toxicities and normal tissue constraints are discussed. This book features unique insights from world-renowned experts in SBRT from North America, Asia, and Europe. It will be necessary reading for radiation oncologists, radiation oncology residents and fellows, medical physicists, medical physics residents, medical oncologists, surgical oncologists, and cancer scientists. |
| car t therapy lung cancer: Molecular Pathology of Lung Cancer Philip T. Cagle, Timothy Craig Allen, Mary Beth Beasley, Lucian R. Chirieac, Sanja Dacic, Alain C. Borczuk, Keith M. Kerr, 2012-06-14 As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff. |
| car t therapy lung cancer: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| car t therapy lung cancer: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| car t therapy lung cancer: Chris Beat Cancer Chris Wark, 2021-01-05 Now in paperback, the Wall Street Journal best-selling guide to charting a path from cancer to wellness through a toxin-free diet, lifestyle, and therapy--created by a colon cancer survivor. Millions of readers have followed Chris Wark's journey on his blog and podcast Chris Beat Cancer, and in his debut work, he dives deep into the reasoning and scientific foundation behind the approach and strategies that he used to successfully heal his body from stage-3 colon cancer. Drawing from the most up-to-date and rigorous research, as well as his deep faith, Wark provides clear guidance and continuous encouragement for his healing strategies, including his Beat Cancer Mindset; radical diet, and lifestyle changes; and means for mental, emotional, and spiritual healing. Packed with both intense personal insight and extensive healing solutions, the Wall Street Journal best-selling Chris Beat Cancer will inspire and guide you on your own journey toward wellness. |
| car t therapy lung cancer: Adjuvant Therapy for Breast Cancer Monica Castiglione, Martine J. Piccart, 2009-07-11 Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable. |
| car t therapy lung cancer: Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Regenerative Medicine, 2020-08-27 Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop. |
| car t therapy lung cancer: Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications Susan C. Frost, Robert McKenna, 2013-10-22 The study of carbonic anhydrase has spanned multiple generations of scientists. Carbonic anhydrase was first discovered in 1932 by Meldrum and Roughton. Inhibition by sulfanilamide was shown in 1940 by Mann and Keilin. Even Hans Krebs contributed to early studies with a paper in 1948 showing the relationship of 25 different sulfonamides to CA inhibition. It was he who pointed out the importance of both the charged and uncharged character of these compounds for physiological experiments. The field of study that focuses on carbonic anhydrase (CA) has exploded in recent years with the identification of new families and isoforms. The CAs are metalloenzymes which are comprised of 5 structurally different families: the alpha, beta, gamma, and delta, and epsilon classes. The alpha class is found primarily in animals with several isoforms associated with human disease. The beta CAs are expressed primarily in plants and are the most divergent. The gamma CAs are the most ancient. These are structurally related to the beta CAs, but have a mechanism more similar to the alpha CAs. The delta CAs are found in marine algae and diflagellates. The epsilon class is found in prokaryotes in which it is part of the carboxysome shell perhaps supplying RuBisCO with CO2 for carbon fixation. With the excitement surrounding the discovery of disease-related CAs, scientists have redoubled their efforts to better understand structure-function relationships, to design high affinity, isotype-specific inhibitors, and to delineate signaling systems that play regulatory roles over expression and activity. We have designed the book to cover basic information of mechanism, structure, and function of the CA families. The authors included in this book bring to light the newest data with regard to the role of CA in physiology and pathology, across phylums, and in unique environmental niches. |
| car t therapy lung cancer: Encyclopedia of Behavioral Medicine Marc D. Gellman, J. Rick Turner, |
| car t therapy lung cancer: Brain Tumor Immunotherapy Linda M. Liau, Donald P. Becker, Timothy F. Cloughesy, Darell D. Bigner, 2000-11-10 An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics. |
| car t therapy lung cancer: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| car t therapy lung cancer: Advances in Radiation Therapy M. Guckenberger, S.E. Combs, D. Zips, 2018-04-12 Developments in radiation oncology have been key to the tremendous progress made in the field in recent years. The combination of optimal systemic treatment and local therapy has resulted in continuing improved outcomes of cancer therapy. This progress forms the basis for current pre-clinical and clinical research which will strengthen the position of radiation oncology as an essential component of oncological care. This book summarizes recent advances in radiotherapy research and clinical patient care. Topics include radiobiology, radiotherapy technology, and particle therapy. Chapters cover a summary and analysis of recent developments in the search for biomarkers for precision radiotherapy, novel imaging possibilities and treatment planning, and advances in understanding the differences between photon and particle radiotherapy. Advances in Radiation Therapy is an invaluable source of information for scientists and clinicians working in the field of radiation oncology. It is also a relevant resource for those interested in the broad topic of radiotherapy in general. |
| car t therapy lung cancer: Oncologic Critical Care Joseph L. Nates, Kristen J. Price, 2019-10-30 This major reference work is the most comprehensive resource on oncologic critical care. The text reviews all significant aspects of oncologic ICU practices, with a particular focus on challenges encountered in the diagnosis and management of the critically ill cancer patient population. Comprised of over 140 chapters, the text explores such topics as the organization and management of an oncologic ICU, diseases and complications encountered in the oncologic ICU, multidisciplinary care, surgical care, transfusion medicine, special patient populations, critical care procedures, ethics, pain management, and palliative care. Written by worldwide experts in the field, Oncologic Critical Care is a valuable resource for intensivists, advance practice providers, nurses, and other healthcare providers, that will help close significant knowledge and educational gaps within the realm of medical care for critically ill cancer patients. |
| car t therapy lung cancer: CD4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential B. Kyewski, Elisabeth Suri-Payer, 2006-01-09 The vertebrate immune system defends the organism against invading pathogens while at the same time being self-tolerant to the body’s own constituents thus preserving its integrity. Multiple mechanisms work in concert to ensure self-tolerance. Apart from purging the T cell repertoire from auto-reactive T cells via negative selection in the thymus dominant tolerance exerted by regulatory T cells plays a major role in tolerance imposition and maintenance. Among the various regulatory/suppressive cells hitherto described, CD4+CD25+ regulatory T cells (Treg) and interleukin-10 producing T regulatory 1 (Tr1) cells have been studied in most detail and are the subject of most articles in this issue. Treg, also called natural regulatory T cells, will be traced from their intra-thymic origin to the site of their action in peripheral lymphoid organs and tissues. The repertoire of Treg is clearly biased towards recognition of self-antigens, thereby potentially preventing autoimmune diseases such as gastritis and oophoritis. Regulatory T cells, however also control infections, allergies and tolerance to transplanted tissues and this requires their induction in the periphery under conditions which are not yet fully understood. The concept of dominant tolerance, by far not novel, will offer new insights and hopefully tools for the successful treatment of autoimmune diseases, improved cancer immunotherapy and transplant survival. The fulfillment of these high expectations will, however, require their unambiguous identification and a better understanding of their mode of action. |
| car t therapy lung cancer: Oxygen Sensing , 2004-05-10 The ability of cells to sense and respond to changes in oxygenation underlies a multitude of developmental, physiological, and pathological processes. This volume provides a comprehensive compendium of experimental approaches to the study of oxygen sensing in 48 chapters that are written by leaders in their fields. |
| car t therapy lung cancer: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
| car t therapy lung cancer: Immuno-oncology Olivier Michielin, George Coukos, 2015 Over the last decade, immuno-oncology has witnessed an astonishing pace of discovery and innovation translating into unprecedented successes in the clinical setting, arguably representing one of the most profound and transforming revolution in the history of cancer therapy. This book provides a concise and accurate outline of the main developments in major tumor types including melanoma, lung, breast, brain and renal cell cancers. In addition, transversal chapters that describe the commonalities of some of the therapeutic strategies are provided to cover topics like immune checkpoint biology, T cell engineering or rational combination therapies. Each chapter has been authored by senior key opinion leaders in their respective fields to provide the most up-to-date view on cancer immuno-oncology. To reflect on the key translational aspect of immuno-oncology, all chapters are making explicit connections between basic science discoveries and the resulting translational therapeutic strategies. Immuno-Oncology will be an invaluable source of information for scientists interested in the translation of basic immunology into the clinical practice, as well as for clinician interested in deepening their knowledge of current and upcoming immune strategies in the fight against cancers. |
| car t therapy lung cancer: Cancer Patient Survival National Cancer Institute (U.S.), 1976 |
| car t therapy lung cancer: Cancer Stem Cells in Lung Cancer Koji Okudela, 2011 Of the many markers for cancer stem cells (CSCs) in lung cancer reported to date, the cell surface antigen CD133, nuclear ß-catenin accumulation, the side population phenotype, and high aldehyde dehydrogenase (ALDH) activity seem to be most reliable. This book reviews the results of studies on lung CSCs and discusses the significance of these markers from a biological, pathological, and clinical viewpoint. Twenty-seven lung cancer cell lines (nine small cell lung carcinoma (SCLC) cell lines and eighteen non-small cell lung carcinoma (NSCLC) cell lines) were examined for mRNA and protein expression and fractions of cells with activity. |
| car t therapy lung cancer: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| car t therapy lung cancer: Diagnosis and Treatment of Lung Cancer Frank C. Detterbeck, 2001 Access comprehensive, multidisciplinary guidance on the diagnosis and treatment of lung cancer! This new resource addresses the full range of clinical issues in diagnosis, staging, and treatment, as well as the latest scientific data and evidence-based guidelines. A user-friendlyorganization provides quick reference to data summaries, as well as more comprehensive and detailed information for readers who wish to explore topics in depth. Features contributions by authors from many different disciplines, to ensure a balanced approach. Addresses the clinical issues seen in practice, with the inclusion of basic science research topics that are likely to be put into clinical practice soon. Integrates evidence-based medicine throughout. Assesses the strength of all available dataenabling readers to weigh different arguments and make decisions based on medical issues, values, and the availability and efficacy of interventionsusing a data rating system. Addresses difficult, but clinically relevant issues for which limited data is available. Enables readers to quickly reference findings and data in data summary statements and summary tables. |
| car t therapy lung cancer: Childhood Cancer and Functional Impacts Across the Care Continuum National Academies of Sciences Engineering and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Childhood Cancers and Disability, 2021-09-09 Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas. |
| car t therapy lung cancer: Cancer Immunotherapy Principles and Practice Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, 2017 Part 1: Intratumoral Signatures Associated With Immune Responsiveness |
| car t therapy lung cancer: Advances in Cancer Biomarkers Roberto Scatena, 2015 At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and polluted knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation. |
| car t therapy lung cancer: Textbook of Lung Cancer, Second Edition Heine Hansen, 2008-03-17 Textbook of Lung Cancer, 2nd edition, published in association with the European Society of Medical Oncology, is a comprehensive and multidisciplinary text, which examines all aspects of this disease, with contributions from a multinational team of authors on etiology, epidemiology, molecular biology, pathology, smoking, detection and management, clinical features, staging and prognostic factors, surgery, radiotherapy and chemotherapy. It provides essential information and guidance for specialist trainees in oncology, and for the many physicians and specialists involved in the field of lung cancer. |
r/Cars - For Car Enthusiasts - Reddit
r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY guides, advice, stories, and more.
Former CarMax employee here. If you plan to go in for an ... - Reddit
Feb 3, 2021 · Where younger an estimated value and when you come in our car buyer puts in his notes and we show you side by side. Where you thought you were and didn't mention that stains in the seat and curbed rims, and half inch dust in the …
How much do car salesmen REALLY make? : r/askcarsales - Reddit
Apr 26, 2022 · Is 6 figures in car sales the norm? EDIT: 25M, single, no kids. Currently in civil engineering with $78k salary in LCOL area (central texas). Seems like folks are making well over $100k in car sales (without needing a college degree). …
Hoseheadforums.com Home
Aug 17, 2013 · Bodnar Motorsports building new car for 2019 viewed (10751) Wicked Energy Gum to Sponsor the Northwest Focus Midget Series viewed (8765) Heartland Motorsports Park Adds American Sprint Car Series Events to 2019 Schedule. …
best places to search for used cars : r/cars - Reddit
Sep 7, 2018 · r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY guides, advice, stories, and more.
Allogeneic CAR T Cells Targeting DLL3 Are Ef cacious and …
Allogeneic CAR T cell therapy or “off-the-shelf” CAR T therapy that utilizes T cells from healthy donors may greatly reduce the time between patient enroll-ment and treatment and may also …
Ligand-based, piggyBac-engineered CAR-T cells targeting
Original Article Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers Thanyavi Chinsuwan, 1,2 Koichi Hirabayashi, …
PTK7-Targeting CAR T-Cells for the Treatment of Lung …
Aug 12, 2021 · support PTK7 as a therapeutic target suitable for CAR T-cell therapy that could be applied for lung cancers and many other solid cancers with PTK7 overexpression. Keywords: …
CAR T cell therapy and the tumor microenvironment: …
allow CAR T cell therapy to overcome the challenges presented by the TME before providing our outlook on directions and potential applications (Table 1). ... Chemokines CXCR5-expressing …
Mesothelin-targeted CAR-T cell therapy for solid tumors
REVIEW Mesothelin-targeted CAR-T cell therapy for solid tumors Astero Klampatsa a, Vivian Dimou a and Steven M. Albeldab aThoracic Oncology Immunotherapy Group, Division of …
DLL3: an emerging target in small cell lung cancer - BioMed …
receptor (CAR) T cell therapy, Delta-like ligand 3 (DLL3), Immuno-oncology therapy, Neuroendocrine, Small cell lung cancer (SCLC), Targeted therapy Background Lung cancer is …
Chimeric antigen receptor T-cell (CAR-T) therapy
What is CAR-T therapy? CAR-T therapy is a treatment that uses your own immune system to destroy cancer cells. Why do I need CAR-T therapy? In the UK, CAR-T therapy is currently …
New CAR T-cell strategy highly effective against small cell …
in small cell lung cancer models," recently published in the Journal of Clinical Investigation. The research was a collaborative effort with ... The effectiveness of CAR T-cell therapy has so far ...
WHO MODEL LISTS OF ESSENTIAL MEDICINES CANCER …
A.8 CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma – EML A.12 Cyclin-dependent kinase 4/6 inhibitors for hormone receptor positive/ HER2-negative advanced …
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell …
Lung cancer is a common malignant tumor with high morbidity and mortality, which has attracted wide atten-tion of researchers [1–4]. More and more treatments have been applied to lung …
B7-H3 specific CAR-T cells exhibit potent activity against …
receptor (CAR) T cell therapy has overcome cancer immune tolerance and progressed considerably in liquid cancer treatment. ... and lung cancer, are increasing [17]. The target …
CT041 CAR T cell therapy for Claudin18.2-positive metastatic …
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer ... creatic cancer. Lung metastasis was found after 5 months during routine post-surgery follow-up. S-1 …
Lung Cancer and other Malignancies PTK7-Targeting CAR T …
Despite great success in treating hematological malignancy, CAR T-cell therapy in solid tumor is still in its infancy with scant objective response seen [4]. Among various factors constraining …
The antitumor capacity of mesothelin-CAR-T cells in targeting …
For both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely fol- ...
Anti-mesothelin CAR-T immunotherapy in patients with …
ness of MSLN-targeting CAR-T cell therapy [17, 22, 23]. Although CAR-T therapy has proved highly efficacious against hematological tumors, several challenges remain for CAR-T therapy …
Phase I clinical trial of EGFR-specific CAR-T cells ... - Springer
receptor (CAR) T-cell therapy has become a robust thera-peutic approach for CD19 + hematological malignancies (Davila et al. 2015; Tran et al. 2017). However, the CAR-T-cell …
Severe delayed pulmonary toxicity following PD‐L1–specific …
CAR-T cell therapy for non-small cell lung cancer Heping Liu 2† , Yuxiang Ma 3† , Chaopin Yang 1,4† , Shangzhou Xia 2 , Qiuzhong Pan 1,4 , Hongyun Zhao 3 ,
LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell …
LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer Ziming Hu, Xiaohu Zheng, Defeng Jiao, Yonggang Zhou, Rui Sun, Baolong Wang, Zhigang ... Statistical analysis …
Ligand-based, piggyBac-engineered CAR-T cells targeting
Original Article Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers Thanyavi Chinsuwan, 1,2 Koichi Hirabayashi, …
PD-1 blockade does not improve efficacy of EpCAM-directed …
Currently, several clinical trials for CAR T-cell in the treatment of lung cancer are underway [10]. The epithelial cell adhesion molecule (EpCAM) may represent a target for CAR T-cell therapy …
Harnessing the chemokine system to home CAR-T cells into …
ceptor (CAR)-T cell therapies. The trafficking of CAR-T cells into tumors is considered one of the first challenges in developing effective CAR-T cell therapy against solid cancers, as there is …
Review Articles Chimeric Antigen Receptor-T Cells in …
Jan 13, 2025 · EpCAM IMC001 China EpCAM CAR-T therapy in advanced GI cancers Luo et al31 (NCT05028933) CDH17 CHM-2101 The United States Phase I/II CAR-T therapy targeting …
Cytokine Release Syndrome After Modified CAR-NK Therapy …
tumors, is a novel approach for treating cancer1. Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most commonly used cell therapies that uses CARs-engineered T cells …
Clinical development of CAR T cell therapy in China: 2020 …
REVIEW ARTICLE OPEN Clinical development of CAR T cell therapy in China: 2020 update Jianshu Wei 1, Yelei Guo , Yao Wang 1, Zhiqiang Wu , Jian Bo2, Bin Zhang3, Jun Zhu4 and …
CAR-T Cell Therapies: How much for survival? - Cancer
million dollars in CAR-T R&D between 1993 and 2017. By March 2017, 91% of CAR-T trials had an academic sponsor. Similarly, CAR-T therapies stirred private funding and investors’ interest. …
CD19 CAR-T cell therapy in a pediatric patient with MDA5 ...
Case repor t CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease Andre´ s Parı´s-Mun˜ oz,1,20 Rosa M. Alcobendas …
Patient Information Leaflet for Chimeric Antigen Receptor …
cancer cells. CAR T cell therapy changes some of your body’s own T cells (part of your immune system) to improve their ability to fight your cancer. How CAR T Therapy Works: The immune …
PTK7-Targeting CAR T-Cells for the Treatment of Lung …
support PTK7 as a therapeutic target suitable for CAR T-cell therapy that could be applied for lung cancers and many other solid cancers with PTK7 overexpression. Keywords: chimeric antigen …
Temperature‐Feedback Nanoplatform for NIR‐II Penta
of lung cancer while performing synergistic photothermal therapy (PTT) and tumor-targeting immunotherapy, a theranostic nanoplatform that introduced upconversion nanoparticles …
Chimeric Antigen Receptor (CAR) T-Cell Therapy
cancer cells. CAR-T cell therapy modifies your immune system activity to improve the body’s own ability to fight certain cancers. Lymphocytes, a subtype of white bloods cells, comprise a large …
Cytokine Release Syndrome After Modified CAR-NK Therapy …
hematologic tumors in recent years. Among them, the CAR-NK (natural killer) therapy has shown better efficacy, and less toxicity, than chimeric antigen receptor T-cell (CAR-T) therapy. In our …
Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of ...
• Globally, this is the first ever study of CAR T-cell therapy compared with the current available standard of care, it aims to show whether CAR T-therapy can achieve a better efficacy in late …
CAR T-Cell-Based gene therapy for cancers: new - Frontiers
metastatic melanoma and lung cancers (10). PD-1 and PD-L1 interactions regulate immune escape in the tumor and tumor microenvironment. PD-1 expression on T-cells is a marker of ...
CAR-T therapy - publicdocuments.sth.nhs.uk
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a new type of cancer treatment which involves using your body’s immune system to treat your cancer. The immune system monitors …
ROR1-CAR T-cells are effective against lung and breast …
ROR1-CAR T-cells conferred potent anti-tumor effects. In dynamic culture, CAR T-cells actively entered arterial medium flow, adhered to and infiltrated the tumor mass. ROR1-CAR T-cells …
Exploring treatment options in cancer: tumor treatment …
lung cancer (NSCLC),9 followed by Erlotinib in 2004,10 expanding ... successful application of CAR-T cell therapy by Carl June in 2011 and the FDA approval of Pembrolizumab and …
Targeting glycans for CAR therapy: The advent of sweet CARs …
Chimeric antigen receptor (CAR) T cell therapy has created a paradigm shift in the treatment of hematologic malignancies but has not been as effective toward solid tumors. For such tu- ...
Annals of Oncology abstracts
1018O Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer C. Qi 1, L. Chang ,J.Li,J.Gong, X.Wang 1, Z.Wang ,X.Lu 2,T.He,Y. Ding 2,F.Wu, D. Liu2, L. …
4SCAR2.0: a multi-CAR-T therapy regimen for the treatment …
Tsai-Hua Chung1,5, Liyuan Sheng2,6 and Lung-Ji Chang 1,5 Dear Editor, Chimeric antigen receptor (CAR) gene therapy is a ... One critical factor to the success of CAR-T therapy for …
Review Advances in targeted delivery of mRNA into immune …
Tisagenlecleucel is an autologous CD19-targeted CAR T cell recently approved by the U.S. Food and Drug Administration (FDA), the European Union (EU) and ... TP53 mRNA hepatocellular …
Phase I study of autologous T cells bearing fully-humanized …
The “M5 CAR” was selected. It binds a different epitope than the SS1 scFV. • CAR consists the M5 single-chain variable fragment (scFv) • The costimulatory CD137 (4-1BB) domain enhances …
$VVHVVPHQW DQG 0DQDJHPHQW 3DJH RI DOVR NQRZQ …
&rs\uljkw 7kh 8qlyhuvlw\ ri 7h[dv 0' $qghuvrq &dqfhu &hqwhu 'hwhuplqh li sdwlhqw kdv f\wrnlqh uhohdvh v\qgurph &56 dqg ru lppxqh hiihfwru fhoo dvvrfldwhg qhxurwr[lflw\
Mesenchymal stromal cell delivery of oncolytic …
and lyse lung tumor cells while stimulating CAR-T cell anti-tu-mor activity by release of IL-12 and PD-L1 blocker. The combi-nation of this approach with administration of HER.2-specific CAR …
Low-dose carboplatin modifies the tumor microenvironment …
cancer. Our data show that carboplatin can synergize with CAR T therapy to facilitate early and persistent CAR T cell infiltration and activation within select prostate tumors to maximize …
Targeting disialoganglioside GD2 with chimeric antigen …
GD2.CAR-T cell cytotoxic activity. Conclusions GD2 is a promising target for CAR-T cell therapy in lung cancer. Tazemetostat treatment could be used to upregulate GD2 expression in tumor …
Targeting PD-L1 in non-small cell lung cancer using CAR T …
Lung cancer is the leading cause of cancer-related death in the world1. In the United States, approximately 234,000 ... Chimeric antigen receptor (CAR) T-cell therapy has been …
CAR-T therapy and targeted treatments: Emerging …
CD19 CAR-T therapy.10 However, the same level of success has not yet been attained ... vessel normalization by increasing pericyte coverage in non-small cell lung cancer, and addition of rh …
Management of prolonged cytopenia following CAR T-cell …
Sloan Kettering Cancer Center (MSKCC) from January 2016 to December 2021. Patients who received two or more doses of ... one year of CAR T-cell therapy and all patients except patient 3
Current Status and Perspectives of Dual-Targeting Chimeric …
Dual-targeting CAR T-cell therapy contains CAR T cells recognizing two targets on cancer cells and can overcome the resistence in cancers to Si-CART. We summarize ... ure1, dual …
